Innoviva Inc (INVA, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline. Innoviva Inc has a market cap of $1.47 billion; its shares were traded at around $14.53 with a P/E ratio of 4.10 and P/S ratio of 6.31.
For the last quarter Innoviva Inc reported a revenue of $79.9 million, compared with the revenue of $69.52 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $261.0 million, an increase of 20.2% from last year. For the last five years Innoviva Inc had an average revenue growth rate of 141.9% a year.
The reported diluted earnings per share was $3.53 for the year, an increase of 201.7% from previous year. The Innoviva Inc enjoyed an operating margin of 93.47%, compared with the operating margin of 84.53% a year before. The 10-year historical median operating margin of Innoviva Inc is -326.22%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $14.53, Innoviva Inc is traded at 77.8% discount to its historical median P/S valuation band of $65.40. The P/S ratio of the stock is 6.31, while the historical median P/S ratio is 28.41. The stock lost 11.79% during the past 12 months.
For the complete 20-year historical financial data of INVA, click here.
